host
cell
infect
mediat
bind
angiotensinconvert
enzym
system
dysregul
observ
sarscov
previous
postul
due
axi
downregul
increas
activ
shown
mediat
diseas
protect
sinc
angiotensin
ii
receptor
blocker
arb
ace
inhibitor
mineralocorticoid
receptor
antagonist
mra
increas
receptor
express
tacitli
believ
use
agent
may
facilit
viral
diseas
thu
use
highrisk
patient
cardiovascular
diseas
base
antiinflammatori
benefit
upregul
axi
previous
demonstr
benefit
lung
function
improv
sarscov
infect
hypothes
benefit
treatment
reninangiotensin
system
inhibitor
may
outweigh
risk
least
withheld
infect
mediat
bind
angiotensinconvert
enzym
given
receptor
upregul
angiotensin
ii
receptor
blocker
arb
ace
inhibitor
mineralocorticoid
receptor
antagonist
mra
unclear
clinic
manag
cardiovascular
patient
reconsid
given
antiinflammatori
benefit
upregul
axi
cardiovascular
diseas
previous
demonstr
benefit
improv
lung
function
sarscov
infect
propos
upregul
expressionact
via
cardiac
agent
benefici
counteract
system
dysregul
inflict
due
dysregul
novel
coronaviru
outbreak
caus
origin
wuhan
hubei
provid
central
china
decemb
declar
pandem
march
th
compar
sarscov
caus
outbreak
appear
stronger
rate
transmiss
wherea
sar
infect
exhibit
prolong
clinic
cours
predominantli
involv
respiratori
manifest
clinic
cours
novel
coronaviru
unclear
clinic
insight
wuhan
suggest
patient
exhibit
sever
cardiovascular
damag
underli
cardiovascular
diseas
appear
increas
risk
death
sarscov
belong
betacoronaviru
phylogeni
although
bat
may
natur
reservoir
sarslik
coronaviru
interspeci
transfer
sarscov
could
occur
civet
pangolin
respect
sarscov
strain
identifi
use
angiotensin
convert
enzym
ii
receptor
portal
entri
affect
cell
key
modul
reninangiotensin
system
ra
signal
pathway
involv
regul
vascular
function
includ
regul
blood
pressur
natriuresi
blood
volum
control
normal
ra
system
involv
format
angiotensin
ii
ang
ii
ace
contribut
multipl
cardiovascular
physiolog
pathophysiolog
function
includ
hypertens
myocardi
hypertrophi
cardiac
fibrosi
inflamm
vascular
remodel
atherosclerosi
given
advers
cardiovascular
effect
ra
system
upregul
inhibit
ace
inhibitor
angiotensin
ii
receptor
blocker
arb
mineralocorticoid
receptor
antagonist
mra
critic
manag
variou
cardiovascular
diseas
last
two
decad
identif
involv
counter
regul
classic
ra
system
offer
potenti
new
therapeut
target
exist
membranebound
solubl
form
former
mediat
infect
via
protein
bind
unclear
whether
interfer
manner
contribut
pathogenesi
sar
cardiovascular
damag
observ
rais
question
whether
ra
inhibit
cardiovascular
patient
reassess
set
novel
coronaviru
classic
ra
system
involv
convers
angiotensinogen
renin
angiotensin
ang
ang
metabol
angiotensin
ii
ang
ii
via
dipeptid
carboxypeptidas
angiotensinconvert
enzym
ace
proinflammatori
effect
ang
ii
mediat
ang
ii
type
receptor
recent
receptor
signal
pathway
identifi
import
counter
regulatori
mechan
classic
ra
system
type
integr
membran
glycoprotein
express
predominantli
bronchu
lung
parenchyma
heart
endothelium
kidney
duodenum
small
intestin
monocarboxypeptidas
unlik
homolog
ace
dipeptidas
antagon
ace
inhibitor
wherea
ace
contain
two
activ
catalyt
domain
singl
catalyt
domain
ident
residu
major
substrat
ang
ii
upon
cterminu
cleavag
produc
angiotensin
lphenylalanin
substrat
includ
ang
catalyz
much
lower
affin
noncatalyt
ctermin
domain
share
sequenc
homolog
collectrin
protein
involv
neutral
amino
acid
reabsorpt
intestin
kidney
presenc
disintegrin
metalloproteinas
also
known
enzym
tace
exhibit
ectodomain
shed
result
format
solubl
enzym
also
contain
calmodulin
domain
cytoplasm
tail
influenc
ectodomain
shed
ang
decapeptid
convert
octapeptid
ang
ii
ace
unlik
ace
ang
convert
importantli
ang
ii
convert
ang
rang
antiinflammatori
antioxid
vasodilatori
natriuret
effect
mediat
gpcr
ma
receptor
may
produc
directli
ang
altern
pathway
involv
zinc
metallopeptidas
neprilysin
nep
convers
ang
via
ace
though
significantli
lower
effici
genet
delet
studi
establish
essenti
regul
cardiovascular
function
studi
focus
regul
cardiac
myocyt
cardiac
fibroblast
demonstr
wherea
ang
ii
significantli
reduc
activ
downregul
mrna
cardiac
myocyt
reduc
activ
fibroblast
myocyt
also
significantli
decreas
mrna
product
reduct
mrna
ang
ii
block
inhibitor
mitogenactiv
protein
kinas
kinas
suggest
ang
ii
activ
extracellular
signalregul
kinas
reduc
vivo
murin
studi
show
ang
ii
mediat
loss
membranebound
cardiomyocyt
correl
upregul
activ
prevent
receptor
blockad
cardiac
fibroblast
coronari
endotheli
cell
also
express
tace
reciproc
relationship
extend
cell
type
well
ang
ii
activ
sever
signal
cascad
pkc
signal
pathway
result
myocardi
hypertrophi
increas
fibrosi
bind
ctermin
domain
also
inhibit
proteolyt
function
ace
enzym
promot
bradykinin
function
studi
human
vascular
cardiac
tissu
plasma
show
higher
affin
ace
ang
suggest
inhibitori
effect
ace
may
contribut
protect
effect
treatment
knock
mice
ang
ii
infus
recombin
elimin
pkc
signal
least
partial
respons
attenu
ang
ii
induc
myocardi
hypertrophi
fibrosi
improv
diastol
dysfunct
studi
highlight
role
ma
axi
modul
express
proinflammatori
cytokin
cardiaclung
fibrosi
pulmonari
hypertens
vascular
remodel
figur
given
import
ra
system
cardiovascular
diseas
regul
via
ace
inhibitor
arb
mra
play
essenti
role
manag
cardiovascular
diseas
central
illustr
sever
studi
elucid
role
drug
class
modul
axi
mous
periton
macrophag
mpm
treat
vitro
aldosteron
demonstr
significantli
increas
ace
activ
well
ace
mrna
significantli
reduc
howev
mpm
treat
nadph
oxidas
inhibitor
aldosteron
could
increas
ace
decreas
suggest
effect
mediat
part
nadph
oxidas
effect
also
attenu
treatment
mraeplerenon
human
monocytederiv
macrophag
obtain
patient
heart
failur
one
month
treatment
anoth
mraspironolacton
mgd
show
reduct
ace
activ
reduct
ace
mrna
express
time
activ
increas
mrna
express
increas
mice
treat
two
week
eplerenon
cardiac
activ
increas
twofold
parallel
increas
activ
macrophag
studi
demonstr
mra
reduc
oxid
stress
decreas
ace
activ
increas
activityexpress
suggest
protect
role
play
increas
gener
ang
decreas
format
ang
ii
overal
aldosteron
decreas
transcript
nicotinamid
adenin
dinucleotid
phosphat
oxidasemedi
pathway
vascular
smooth
muscl
cell
potenti
ang
ii
signal
increas
phosphoryl
extracellular
signalregul
kinas
cjun
kinas
jnk
also
depend
reactiv
oxygen
speci
gener
thu
benefici
effect
mra
like
associ
reduct
oxid
stress
differenti
control
angiotensinas
mra
appear
promot
membran
express
suppress
peripher
effect
ang
ii
howev
effect
mra
solubl
remain
unclear
similar
upregul
observ
studi
focus
effect
arb
treatment
spontan
hypertens
rat
shr
treat
olmesartan
demonstr
greater
express
mrna
increas
thorac
aorta
treat
atenolol
hydralazin
exhibit
chang
express
comparison
vessel
wall
dimens
show
olmesartan
select
reduc
thorac
aorta
mediatolumen
ratio
vascular
hypertrophi
unchang
shr
given
atenolol
hydralazin
chang
expressionact
carotid
arteri
treat
anim
possibl
effect
olmesartan
vascular
gene
protein
express
result
reduc
arteri
blood
pressur
rule
given
compar
effect
observ
mice
treat
atenolol
hydralazin
spraguedawley
rat
treat
cours
ang
ii
infus
show
ang
ii
upregul
receptor
downregul
receptor
activ
eno
express
increas
express
hyaluronidas
howev
rat
treat
telmisartan
exhibit
significantli
increas
activ
eno
express
intracardiac
vessel
intermyocardium
well
downregul
local
express
receptor
treatment
telmisartan
also
inhibit
membran
express
reduc
smad
express
studi
normotens
rat
post
coronari
arteri
ligat
left
ventricular
remodel
dysfunct
exhibit
partial
resolut
follow
losartan
olmesartan
treatment
augment
plasma
concentr
angiotensin
associ
recoveri
cardiac
receptor
mrna
increas
mrna
post
myocardi
infarct
impli
benefici
effect
arb
cardiac
remodel
accompani
direct
blockad
receptor
increas
expressionact
literatur
offer
conflict
result
pertain
arb
use
level
express
myocardium
controversi
aris
differ
cell
surfac
express
plasma
level
spraguedawley
rat
left
coronari
arteri
ligat
myocardi
infarct
plasma
ang
ii
ang
elev
plasma
elev
along
enhanc
cardiac
receptor
mrna
infarct
border
receptor
upregul
observ
remot
myocardium
treatment
ramipril
valsartan
result
increas
plasma
ang
ang
ii
suppress
plasma
ace
activ
howev
neither
monotherapi
combin
therapi
affect
receptor
express
remain
level
compar
nonmyocardi
infarct
control
howev
prior
studi
murin
model
show
ace
upregul
border
infarct
zone
viabl
myocardium
myocardi
infarct
treatment
ramipril
reduc
ace
express
remain
elev
compar
noninfarct
control
recent
studi
murin
model
demonstr
treatment
olmesartan
telmisartan
increas
cardiac
mrna
protein
express
augment
plasma
ang
ii
ratio
result
improv
cardiac
function
allevi
collagen
disposit
experi
suggest
ace
inhibitor
arb
variabl
upregul
express
arb
inhibit
bind
ang
ii
receptor
permit
circul
ang
ii
shunt
convers
studi
suggest
axi
collabor
regul
receptor
may
import
mediat
vascular
cardiac
remodel
effect
ang
ii
mechan
ace
inhibitor
act
complex
although
inhibit
ace
inhibitor
increas
ang
suggest
clinic
effect
partli
mediat
angiotensinas
ace
inhibitor
inhibit
convers
ang
ang
ii
inhibit
hydrolysi
bradykinin
ace
inhibit
promot
vasodilatori
effect
bradykinin
improv
endotheliumdepend
vasodil
increas
prostaglandin
nitric
oxid
product
regul
receptor
studi
elucid
effect
ace
inhibit
gene
shown
inhibit
ang
ii
synthesi
regul
mrna
activ
howev
ace
inhibit
alon
combin
losartan
demonstr
increas
plasma
reduc
plasma
ang
ii
compar
degre
mrna
upregul
seen
post
losartan
monotherapi
combin
losartan
lisinopril
result
suppress
upregul
mrna
suggest
ace
inhibitor
may
overrid
signal
regul
transcript
although
ang
ii
predomin
substrat
also
convert
ang
ang
turn
could
convert
ang
via
ace
ang
directli
convert
ang
via
nep
though
less
favor
kinet
baselin
thu
one
assum
ace
inhibitor
disrupt
balanc
catalyt
activ
ace
result
favor
activ
axi
overal
given
demonstr
antiinflammatori
antifibrot
antithrombot
effect
associ
axi
upregul
could
serv
valuabl
therapeut
target
multipl
murin
studi
demonstr
modul
ra
pathway
though
unclear
effect
translat
human
clinic
studi
assess
pharmacokinet
pharmacodynam
solubl
treatment
healthi
volunt
known
comorbid
show
decreas
plasma
ang
increas
ang
ang
effect
blood
pressur
heart
rate
common
side
effect
includ
diarrhea
headach
antibodi
develop
suggest
elicit
immun
respons
singl
repeat
dose
howev
studi
investig
immunogen
rhace
requir
patient
ard
sepsi
serum
level
ace
ang
ii
elev
studi
focus
microvascular
dysfunct
sepsi
show
degre
elev
plasma
renin
ang
ii
correl
extent
organ
failur
degre
microvascular
dysfunct
especi
patient
receiv
exogen
vasoconstrictor
also
neg
correl
reoxygen
rate
concentr
plasma
renin
ang
ii
pilot
clinic
trial
patient
ard
treat
exhibit
decreas
plasma
ang
ii
elev
plasma
ang
surfact
proteind
involv
innat
immun
concentr
treat
patient
also
reduc
albeit
statist
insignificantli
owe
intrasubject
variabl
baselin
imbal
although
attenu
ra
mediat
infus
medic
show
improv
physiolog
clinic
measur
ard
studi
addit
pilot
studi
investig
effect
human
pulmonari
arteri
hypertens
character
reduc
activ
treatment
show
improv
cardiac
output
coincid
maximum
suppress
plasma
cytokin
reduct
nitrotyrosin
level
improv
peripher
vascular
resist
well
improv
renal
perfus
ongo
clinic
studi
assess
modul
ra
axi
includ
assess
rel
activ
ace
diabet
patient
follow
treatment
candesartan
overexpress
cardiac
progenitor
cell
assess
enhanc
repar
function
potenti
attenu
myocardi
ischemiainduc
cardiac
damag
evid
target
axi
go
interest
clinic
set
given
observ
cardioprotect
effect
vivo
murin
vitro
cell
cultur
model
howev
investig
requir
demonstr
whether
favor
experiment
effect
could
translat
clinic
benefit
sever
report
note
associ
cardiac
involv
cohort
studi
hospit
patient
confirm
sever
patient
present
elev
troponin
creactiv
protein
ntprobnp
suggest
myocardi
injuri
anecdot
studi
report
patient
present
cardiac
magnet
reson
imaginingverifi
acut
myopericard
systol
dysfunct
masquerad
diffus
stelev
myocardi
infarct
elev
cardiac
marker
absenc
obstruct
coronari
diseas
cohort
studi
confirm
hospit
patient
wuhan
china
acut
myocardi
injuri
shock
arrhythmia
observ
patient
cardiac
injuri
found
high
risk
death
time
symptom
onset
time
admiss
epidemiolog
studi
emerg
china
itali
affect
area
data
avail
elucid
clinic
present
patient
cardiovascular
damag
associ
novel
coronaviru
regard
current
sever
clinic
studi
investig
effect
ra
inhibit
regul
ongo
studi
assess
impact
ace
inhibitor
arb
treatment
sever
prognosi
patient
along
line
two
recent
launch
trial
test
effect
losartan
among
patient
hospit
ambulatori
studi
launch
evalu
effect
continu
vers
replac
withdraw
ra
inhibitor
clinic
outcom
patient
cardiovascular
diseas
also
ongo
pilot
studi
assess
effect
treatment
patient
current
data
support
conclus
effect
use
ra
inhibitor
patient
sarscov
emerg
guangdong
provinc
china
emerg
wuhan
china
close
relat
betacoronavirus
whose
affect
receptor
time
unknown
approxim
sequenc
similar
strain
virus
translat
similar
biolog
properti
recent
studi
confirm
exploit
entri
thu
may
target
similar
spectrum
cell
sarscov
bind
via
spike
protein
surfac
unit
protein
bind
facilit
viral
attach
target
cell
follow
receptor
bind
viru
must
gain
access
host
cytosol
accomplish
aciddepend
proteolyt
cleavag
protein
cellular
serin
proteas
similar
protein
prime
sarscov
figur
given
sequenc
similar
sarscov
affect
receptor
recent
confirm
viral
entri
reason
hypothes
may
act
similarli
respect
util
host
endocytosi
machineri
subsequ
viru
propag
infect
upon
bind
cleavag
protein
site
allow
fusion
viral
cellular
membran
sarscov
intern
penetr
earli
endosom
clathrindepend
manner
viral
bind
appear
affect
activ
presenc
calmodulin
inhibitor
promot
ectodomain
cleavag
case
possibl
shed
also
mediat
given
one
clinic
featur
note
patient
presenc
cytokin
storm
increas
plasma
concentr
gcsf
also
possibl
shed
may
mediat
cytokin
dysregul
shed
contribut
downregul
membranebound
observ
sever
acut
lung
injuri
ectodomain
shed
increas
concentr
plasma
remain
catalyt
activ
though
function
solubl
remain
unclear
patient
advanc
heart
failur
plasma
activ
increas
direct
proport
worsen
clinic
statu
reduct
eject
fraction
correl
advers
clinic
outcom
sinc
downregul
bound
observ
sever
acut
lung
injuri
post
myocardi
infarct
concentr
solubl
appear
correl
clinic
outcom
heart
failur
patient
possibl
suggest
concentr
solubl
may
correl
extent
tissu
damag
sustain
may
correl
degre
system
inflammatori
pathway
upregul
evid
suggest
solubl
abl
regul
system
ang
ii
clinic
trial
shown
could
convert
system
ang
ii
ang
play
patholog
compensatori
counter
regulatori
role
induc
ectodomain
shed
result
reduct
entri
site
infect
cell
possibl
follow
transcript
protein
fuse
directli
host
cell
membran
directli
promot
infect
neighbor
cell
result
format
multinucl
syncytia
format
multinucl
cell
would
allow
viru
spread
without
detect
neutral
virusspecif
antibodi
otherwis
follow
replic
transcript
complet
virion
assembl
golgi
would
result
transport
viru
vesicl
releas
exocytosi
set
full
virion
assembl
exocytosi
unclear
ectodomain
shed
would
favor
propag
infect
regardless
complet
virion
assembl
clear
membranebound
would
play
physiolog
role
replic
novel
viru
question
remain
whether
use
ace
inhibitor
arb
mra
avoid
set
sarscov
infect
given
agent
upregul
express
activ
lipopolysaccharid
lp
induc
acut
lung
injuri
ali
mous
model
exhibit
decreas
express
lung
inflammatori
injuri
howev
amelior
inject
cell
transfect
result
improv
lung
function
lung
injuri
treatment
mice
ace
inhibitor
arb
also
allevi
lpsinduc
pneumon
injuri
prior
studi
shown
sarscov
protein
exagger
acut
lung
failur
deregul
reninangiotensin
system
howev
sarscov
spikemedi
lung
failur
could
rescu
inhibit
receptor
adequ
data
effect
ra
inhibit
patient
avail
ongo
clinicalobserv
studi
conduct
downregul
membranebound
promot
mediat
ectodomain
shed
result
increas
concentr
solubl
without
compromis
viral
propag
hypothes
would
result
overal
downregul
pathway
would
contribut
sever
inflamm
system
dysregul
observ
thu
patient
cardiovascular
diseas
use
ace
inhibitor
arb
mra
may
favor
method
endogen
upregul
compensatori
mechan
provid
antiinflammatori
antifibrot
antithrombot
support
well
reduct
progress
vascularcardiac
remodel
heart
failur
sever
societi
includ
american
colleg
cardiolog
american
heart
associ
heart
failur
societi
america
european
societi
cardiolog
recommend
continu
ra
system
antagonist
given
lack
conclus
data
link
upregul
system
tissu
increas
suscept
patient
cardiovascular
diseas
base
review
hypothes
cardiovascular
patient
remain
ra
system
inhibitor
given
protect
effect
pathway
ra
blockad
proven
increas
risk
associ
cardiac
involv
requir
bind
ra
system
pathway
counterbal
ra
system
result
activ
antiinflammatori
pathway
ace
inhibitor
arb
mra
upregul
activ
express
data
requir
determin
regul
patient
cardiovascular
diseas
would
help
improv
clinic
outcom
central
illustr
ra
system
interact
normal
ang
convert
ang
ii
via
ace
could
inhibit
ace
inhibitor
proinflammatori
effect
ang
ii
mediat
sever
way
zona
glomerulosa
adren
medulla
stimul
aldosteron
secret
bind
mineralocorticoid
receptor
promot
water
reabsorpt
increas
salt
retent
inhibit
mra
posterior
pituitari
ang
ii
stimul
antidiuret
hormon
secret
promot
water
retent
